Please login to the form below

Not currently logged in
Email:
Password:

Claes Buxfeldt joins NDA

He becomes its new HTA director

AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board.

During the past 18 years, Buxfeldt’s career has seen him work on a variety of disease areas, supporting more than 30 molecules/brands in global positions.

He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.

Dr Werner Van den Eynde, vice president for the NDA advisory board, said: “We are very happy to welcome Claes on board as our new HTA director.

“Claes’ expertise will allow us to provide an even better service to our clients.”

Buxfeldt’s new role at NDA will see him drive and develop the group’s service offerings in the HTA area.

21st March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics